RecruitingPhase 2Phase 3NCT06798363

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma： a Prospective Study

Sponsor

West China Hospital

Enrollment

24 participants

Start Date

May 2, 2025

Study Type

INTERVENTIONAL

Conditions

Infantile Hemangioma

Summary

The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).

Eligibility

Min Age: 1 MonthMax Age: 4 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called propranolol for people with infantile hemangioma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Month to 4 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGpropranolol

different dose

Locations(1)

West China Hospital of Sichuan University

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06798363